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Abstract
The diversity of fungal species comprising the lung mycobiome is a reflection of exposure to environmental
and endogenous filamentous fungi and yeasts. Most lung mycobiome studies have been culture-based. A
few have utilized next generation sequencing (NGS). Despite the low number of published NGS studies,
several themes emerge from the literature: (1) moulds and yeasts are present in the human respiratory tract,
even during health; (2) the fungi present in the respiratory tract are highly variable between individuals;
and (3) many diseases are accompanied by decreased diversity of fungi in the lungs. Even in patients
with the same disease, different patients have been shown to harbor distinct fungal communities. Those
fungal species present in any one individual may represent a patient’s unique environmental exposure(s),
either to species restricted to the indoor environment, for example, Penicillium, or species found in the
outdoor environment such as Aspergillus, wood and vegetation colonizing fungi and plant pathogens. In
addition to causing clinical fungal infections, the lung mycobiome may have inflammatory effects that can
cause or worsen lung disease. Most respiratory diseases that have been studied, have been associated
with decreases in fungal diversity. However, none of these diversity studies distinguish between accidental,
transient fungal colonizers and true residents of the respiratory tract. Where does Aspergillus feature in the
mycobiomes of the respiratory tract? Do these mycobiomes reflect the diversity of fungi in outdoor and
internal environments? These intriguing questions are explored here.
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Introduction
Many different manifestations of aspergillosis are well under-
stood including allergic aspergillosis (rhinosinusitis and bron-
chopulmonary) (>10 million worldwide), chronic pulmonary
and rhinosinus aspergillosis (∼3 million worldwide), invasive
aspergillosis (incidence >300000 annually), and superficial dis-
ease (notably keratitis, otomycosis, and trauma or burn wound
infections). These conditions are seen worldwide.1
Allergic bronchopulmonary aspergillosis (ABPA) presents as
poorly controlled asthma, production of mucous plugs, and/or
mucoid impaction, “pneumonia” and serologically positive in
patients with asthma. Poor asthma control in severe asthma
is associated with Aspergillus sensitization. In cystic fibrosis it
presents with pulmonary infiltrates and worsening lung func-
tion. Extrinsic allergic bronchoalveolitis may be attributable to
Aspergilli.
Chronic pulmonary aspergillosis (CPA) usually occurs in
patients with underlying pulmonary disease and presents with
persistent cough, hemoptysis, weight loss, breathlessness, and
fatigue. It may lead to respiratory failure through progressive
fibrosis (destroyed lung).
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Invasive aspergillosis (IA) occurs in hematological malignancy
after transplantation, in those with chronic obstructive pul-
monary disease (COPD) and those treated with corticosteroids.
IA is now reported in other immunocompromised patient popu-
lations, such as intensive care unit (ICU) patients, patients given
anti-tumor necrosis factor (anti-TNF) therapy, and patients with
AIDS. The early clinical features are usually silent; pyrexia is un-
usual, and later manifestations include chest discomfort and mild
hemoptysis.
Many more fungi are present in outdoor and environments,
some of which may impact on human health, beyond the famil-
iar clinical manifestations of aspergillosis. What is not known
is whether the presence of other moulds and yeasts in the res-
piratory tract impact on or exacerbate diseases associated with
Aspergillus.
Allergic bronchopulmonary mycosis (ABPM) is a
hypersensitivity-mediated disease of the lower airways caused
by environmental fungi. The predominant etiologic agents
include Candida albicans, Schizophyllum commune, species
of Alternaria, Bipolaris, Cladosporium, Curvularia, Fusarium,
Penicillium, Pseudallescheria, Rhizopus, Saccharomyces, Stem-
phylium, and Trichosporon.2 Many of these moulds are found
in both outdoor and indoor air.
This review explores the diversity of the mycoflora (the fun-
gal ecosystem) in outdoor and indoor air, and dust from out-
door and indoor environments, and discusses how this matches
the mycobiome of the respiratory tract considering how much
air is inspired (approximately 40 cubic meters every 24 hours
by an adult) and what is the proportion of Aspergillus in re-
lation to other environmental moulds. Is Aspergillus under- or
over-represented in the human respiratory tract? This may help
to explain the pathophysiology of pulmonary aspergillosis un-
derlying the relationship between mould pollution of outdoor
and indoor environments and these diseases. One major limi-
tation of these studies is that they do not distinguish between
transient colonization of the respiratory tract or resident flora.
An analogous scenario is the gut mycobiome. There appears to
be an impressive diversity in the gut but one view is that this
is illusory.3 There is a clear division between a small number
of commonly detected species (Candida, Saccharomyces, yeasts
in the Dipodascaceae, and Malassezia species) and a long list of
taxa that have been reported only once. Furthermore, an inves-
tigation into the ecology of these rare species reveals that many
of them are incapable of colonization or long-term persistence
in the gut. This thinking should be kept in mind when reviewing
the long list of taxa in the respiratory tract.
There are a number of challenges regarding mycobiome re-
search.4 First, the isolation of nucleic acids from fungal cells
can be problematic and often requires a combination of enzy-
matic, chemical, and mechanical lysis steps. Second, the ability
to discriminate between fungal taxa is influenced by sequencing
primer choice; finally, curated databases for taxonomic assign-
ment and/or the annotation of fungal genomes are lacking, are
incomplete, or inaccurate.
Perhaps the major challenge when reviewing the literature on
the mycobiome of the respiratory tract is an understanding of
the nuances of the various techniques used and how divergent
results have been generated, that is, culture versus nonculture
methodologies, and the various nonculture molecular platforms.
This is beyond the scope of this review. The reader is directed
toward the numerous analyses of the gut mycoflora that have
demonstrated the efficiency of these techniques in identifying a
high number of fungi but also have revealed major discrepancies
between surveys.5,6 Culturomics has emerged recently as a suc-
cessful tool to isolate high number of bacteria from the gut and
to identify new species.5 It has shifted the view on human gut mi-
crobiota by discovering “new” bacterial diversity not previously
captured by metagenomics. However, culturomic methodology
has not yet been comprehensively applied to describe the fungal
population in the human gut or the respiratory tract.
It is against this background and understood limitations of
the methods used that the various surveys of the fungal diversity
within the respiratory tract are discussed.
The mycobiome of outdoor air and dust
While the physical and chemical properties of particulate matter
(PM) pollutants have been extensively studied, relatively little
is known about microbes associated with PM, especially air-
borne fungi.7 Fungal spores can account for large proportions
of air PM, and some fungi are major pathogens or allergens for
humans. Moreover, air is the primary medium for fungal dis-
persal.8 Hitherto, a few studies carried out provide only limited
insight into airborne fungi associated with PMs. Airborne fungi
associated with PMs have been reported from different regions
of the world.7 A few examples are given here.
To assess the diversity and composition of airborne fungi as-
sociated with PM in Beijing, China, a total of 81 PM samples
were collected, which were derived from PM2.5, PM10 frac-
tions, and total suspended particles during hazy and non-hazy
days.7 The airborne fungal community in these samples was
analyzed using the Illumina Miseq platform with fungi-specific
primers targeting the internal transcribed spacer1 region of the
large subunit rRNA gene. A total of 797040 reads belonging
to 1633 operational taxonomic units were observed. Of these,
1102 belonged to Ascomycota, 502 to Basidiomycota, 24 to Zy-
gomycota, and five to Chytridiomycota. The dominant genera
were Cladosporium, Alternaria, Fusarium, Penicillium, and As-
pergillus. Analysis of similarities revealed that both particulate
matter sizes and air quality levels significantly affected the air-
borne fungal community composition. The relative abundance of
many fungal genera was found to significantly differ among var-
ious PM types and air quality levels. Alternaria and Epicoccum
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were more abundant in total suspended particle samples, As-
pergillus in heavy-hazy days and PM2.5 samples, and Malassezia
in PM2.5 samples and heavy-hazy days. Furthermore, temper-
ature and relative humidity were significant factors that deter-
mined the composition of the airborne fungal community. The
results suggest that diverse airborne fungal communities are as-
sociated with particulate matters.
Numerous reports have been published on the association
between the airborne Aspergillus conidia and fine particulates,
while limited studies have focused specifically on the associa-
tion between invasive aspergillosis and ambient fine particulate
air pollution. Liu and colleagues investigated in Taiwan the as-
sociation between ambient fine particulate PM2.5 air pollution
and invasive aspergillosis at a population level.9 They had access
to a collection of long-term and nationwide databases of daily
ambient PM2.5 levels and invasive aspergillosis incidence. A to-
tal of 1000000 patients during the study period (1999–2009)
were included in the data set. The findings suggested a pos-
itive association between PM2.5 concentration and incidence
of aspergillosis. Furthermore, month-wise invasive aspergillosis
case numbers potentially demonstrated lagged pattern following
peaking of PM2.5 concentration, a delay between PM2.5 expo-
sure and invasive aspergillosis, of approximately 1 month was
seen.
The concentration of fungal species and particles (PM10 and
PM2.5) has been investigated in two French hospitals, as well as
ambient parameters (temperature, relative humidity, pressure,
and carbon dioxide).10 Chemical and microbiological air con-
centrations were measured during two campaigns (winter and
summer) and across seven rooms. The study showed that in-
door air contains a complex mixture of chemical and physical
compounds and a variety of fungi: Aspergillus, Penicillium, Al-
ternaria, Cladosporium, and Stachybotrys. Concentrations in the
same order of magnitude were found in both hospitals.
Fungal communities: indoor dust and air—houses
House dust is a complex mixture of inorganic and organic mate-
rial that supports a diverse population of microbes, reviewed by
Rintala and colleagues.11 Filamentous moulds and yeasts are able
to grow and proliferate in dust only if there is enough moisture
present. Most of the fungal population originates from sources
other than the dust itself, these being outdoor air and other out-
door material, such as vegetation or dirt brought into buildings,
occupants of the buildings themselves, including pets and fungal
growth on moist building materials.
Based on numerous culture and nonculture based studies,
Penicillium, Aspergillus, Cladosporium, and about 20 other fun-
gal genera are the most commonly found in dust depending on
the dust type, detection method, type of the indoor environment
and season, among other factors.11,12 Microbial assemblages
in different house dust types usually share the same dominant
species; however, alterations in the composition are caused by
differing sources of microbes for different dust types. For exam-
ple, mattress or pillow dust is dominated by species originating
from the user of the mattress, and temperate climate zones show
higher dust microbial diversity than tropical zones.
The house dust components of fungal origin may include
intact fungal conidia, spores, and spore clumps, as well as frag-
ments of spores and hyphae. The size and shape of intact fun-
gal spores varies from tiny, round to ovoid 2–5 μm conidia
of Aspergillus and Penicillium, to large, oblong 50 μm coni-
dia of Alternaria and Helminthosporium. Fungal fragments vary
in size from submicrometer (<1 μm) particles to larger hyphal
fragments.
The indoor fungal ecosystem is complex and is thought to
depend on dispersal from the outdoor ecosystem and the occu-
pants’ mycobiome combined with selective pressures imposed by
the occupants’ behaviors and the building itself. Early studies ex-
plored the occurrence of fungi in pillows, furniture stuffings, and
upholstery as well as house dust in relation to asthmatic reactions
and allergic sensitization.11 The first studies to explore dusts col-
lected from indoor environments reported the basic findings con-
cerning levels of viable fungi, the prevalent indoor and outdoor
taxa, the strong variation in fungal taxa in indoor air, and the
tendency of indoor materials to accumulate fungal spores over
time that have since been verified by numerous other studies.11
Fungal species capable of proliferating in house in the absence
of moisture include extreme xerophiles: for example, Eurotium
repens, Aspergillus penicilloides and mixed Penicillium species.
Most other moulds, for example, Cladosporium and Alternaria,
are considered to be unable to proliferate under dry indoor con-
ditions but need a liquid water source or excessive indoor hu-
midity.13 These two species are commonly found in outdoor air
in a number of global regions.
The investigation of indoor microbial ecology has been based
primarily on culture, but more recently it has been facilitated by
nucleic acid sequence-based methods, reviewed by Adams and
colleagues.14 Together, these approaches have identified fungi
that grow indoors when moisture is available that are shed from
humans or pets15 and those species that have obvious outdoor
origins.16 From recent studies that have relied on nucleic acid am-
plification (NAAT) techniques to assess total fungal assemblages
it is clear that fungi in settled dust are diverse, that variation be-
tween buildings can be large and fluctuate with the outdoor air,
and that, as a result, there may not be a typical profile of indoor
fungi that distinguishes different types of buildings.17 What are
the processes that influence the dispersal and selection regimes
of moulds in the indoor space? First, it is clear that the majority
of indoor air fungi are derived from outdoor air.11 Second, the
variation in fungal communities between houses, for example, is
large and partly attributable to selection pressures imposed by
resident behavior. A third finding is that airborne fungal com-
munities vary among rooms within a building based on room use
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and water availability. Furthermore, it is expected that cleaning
and cooking patterns and exposure to the outdoors will have a
predictable effect on the composition of the indoor fungal com-
munities and that the air in rooms with water sources (bathrooms
and kitchens) would have a higher burden of resident fungi.
Numerous studies have determined the pattern of fungal di-
versity and composition in indoor air in specific in indoor envi-
ronments in order to identify processes supporting the array of
species. Adams and colleagues surveyed airborne fungal assem-
blages within 1-month time periods at two seasons, indoors and
outdoors, within and across residences at a university housing
facility.14 Fungal communities indoors were diverse and strongly
determined by dispersal from outdoors, and no fungal taxa were
found as indicators of indoor air. There was a seasonal effect on
the fungi found in both indoor and outdoor air, and quantita-
tively more fungal biomass was detected outdoors than indoors.
Interestingly, room and occupant behavior had no detectable
effect on the fungi found in indoor air. These results confirm
previous reports that outdoor air fungi dominate the spectrum
of indoor air. More broadly, this study provides additional sup-
port for the growing evidence that short-distance dispersal, even
on small geographic scales, is a key process in structuring the
often-observed distance–decay biogeographic pattern in fungal
communities.
To determine the diversity of moulds that residential occu-
pants are exposed Tong and colleagues observed that common
skin and environmental fungal taxa dominated air, surface, and
skin samples in residences in Hong Kong.18 The frequency of
how often individuals touch surfaces in their homes appeared to
determine the fungal community structure on occupant residen-
tial surfaces. SourceTracker prediction suggested that some fungi
can be transferred bi-directionally between surfaces and skin
sites (SourceTracker software is designed to predict the source
of microbial communities in a set of samples). In addition, the
study demonstrated a modest but significant association between
indoor airborne bacterial composition and geographic distance
on a city-wide scale but not for fungi. It was clear that airflow
might play a prominent role in driving the spatial variation of
the indoor airborne mycobiome. This and local environmental
factors, including air currents, appear to be stronger determi-
nants of indoor airborne mycobiome than ventilation strategy,
human occupancy, and room type.
Little is known about the indoor fungal ecosystem of green
homes. Green housing is designed to use low-impact materi-
als, increase energy efficiency, and improve occupant health. A
recent study looked at the variability of fungal populations in
green and nongreen homes.19 The fungal diversity in air, bed
dust and floor dust was compared between green and nongreen,
low-income homes in Cincinnati, Ohio, USA. The samples were
collected at baseline (within four months following renovation),
and 12 months after the baseline in the green homes. Paral-
lel sample collection was conducted in nongreen homes. Air
samples were collected by PM2.5 samplers over 5 days. Bed
and floor dust samples were vacuumed after the air sampling
was completed. The DNA sample extracts were analyzed us-
ing ITS amplicon sequencing. Analysis indicated that there was
no clear trend in the fungal communities between green and
nongreen homes. Instead, fungal community differences were
greatest between sample types: air, bed, and floor. Fungal com-
munities also changed substantially between sampling intervals
in both green and nongreen homes for all sample types, poten-
tially indicating that there was very little stability in the fungal
ecosystem.
The fungal composition of household dust has been analyzed
using quantitative polymerase chain reaction (MSQPCR) tech-
nology developed by the US Environmental Protection Agency.20
The presence of 81 mould species in homes in the United States
and the United Kingdom was determined. Dust samples were
obtained from randomly selected homes in the United Kingdom
(11 homes). The mould populations in British homes were com-
pared with those found in typical homes (no visible mould) in
the United States (in the state of Ohio, 45 homes). Only 13
of 81 species screened showed significantly different concentra-
tions in these two sets of homes. Although only a small survey,
the results suggested that typical mould profiles in the United
States (Ohio) and British homes were very similar. Analysis of
26 mould indicator species revealed that the British homes fell
into two clusters, tentatively identified as “atypical” and “typi-
cal” mould conditions. This study was an early demonstration
that nucleic analysis amplification of dust samples could provide
an objective measure of indoor moulds and the potential for
exposure and associated health effects.
The scale of this approach to explore the fungal communi-
ties in homes has been extended to other parts of the globe.21
As part of a worldwide survey of the indoor mycobiota, dust
was collected from nine countries. Analyses of dust samples in-
cluded culture and pyrosequencing. A total 7904 isolates were
recovered; of these, 2717 isolates were identified as belonging
to Aspergillus, Penicillium, and Talaromyces groups. In addi-
tion, the study created a reliable reference sequence database
for next-generation sequencing projects. Fifty-nine Aspergillus
species were identified, including eight undescribed species, 49
Penicillium species of which seven were undescribed and 18 Ta-
laromyces species including three new ones. In total, 568 ITS
barcodes were generated, and 391 β-tubulin and 507 calmod-
ulin sequences, creating a database of alternative identification
markers.
A number of studies suggest that a big proportion of yeasts
in house dust originate from human skin, particularly notable
during months where the ingress of outdoor sources is reduced.
For example, Pitkaranta and colleagues showed that a significant
proportion of fungal diversity in house dust of two nursing home
buildings in Finland during winter months originated from the
basidiomycete subclass Exobasidiomycetidae, consisting mainly
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of Malassezia.22 Generally, winter samples were dominated by
yeasts, while all other seasons were dominated by filamentous
fungi.
Fungal ecosystem: indoor air and dust—hospitals
Fungal contamination in healthcare facilities has been the sub-
ject of numerous studies that have explored transmission of air-
borne spores through ventilation systems and air conditioning
units. Few studies have attempted to correlate the level of fungal
pollution with the occurrence of specific diseases among patients
or hospital staff. However, these studies do provide information
on the diversity of moulds in indoor air and what patients and
staff are exposed to. The degree of contamination by fungi in the
hospital environment may increase dramatically in combination
with various factors, such as the presence of construction activ-
ity, demolition, and a favorable microclimate. Because exposure
to fungi can cause serious health problems, it is clearly essential,
in the above-mentioned risk situations, to evaluate the degree
of contamination in the various environments and to use those
evaluations to determine the risk of infection for patients and
staff alike. It is clear that the use of air handling systems with
in-line filters and the use of air conditioning systems does not
provide complete protection against fungi.
Airborne fungi in hospitals are associated with hospital-
acquired infections. The high diversity of airborne fungi in the
hospital environment has been demonstrated by culture-based
techniques and sequencing-based mycobiome analysis. To iden-
tify the causative airborne microorganisms, Tong and colleagues
used high-volume air samplers for recovering fungi from hospi-
tal air.23 Species identification was performed by culture-based
methods and DNA sequencing analysis with the Illumina MiSeq
and HiSeq 2000 sequencing systems. The distribution charac-
teristics of fungi were investigated using heat map analysis of
four departments, including the respiratory intensive care unit,
intensive care unit, emergency room, and outpatient department.
The prevalence of Aspergillus species was approximately 17%
to 61%, and the proportion of Aspergillus fumi gatus among
Aspergillus species was from 34% to 50% in the four depart-
ments.
Aspergillus as a member of the mycobiome of the
respiratory tract
Molecular techniques have revealed a previously unappreciated
complexity to the mycobiome of the respiratory tract that has re-
newed an interest in the interactions between host, fungi, and the
pathogenesis of exacerbations of chronic lung disease. The com-
position of the lung microbiome is controlled by fungal immigra-
tion (i.e., inhalation), elimination, and relative growth rates of
the constituent species, reviewed by Dickson and colleagues.24
All these factors change dramatically in chronic lung disease
and further during exacerbations. The features of exacerbations
include increased fungal burden and decreased diversity of fun-
gal communities. It has been proposed that exacerbations are
occasions of respiratory tract dysbiosis—a disorder of the res-
piratory tract fungal ecosystem with negative effects on host
biology and physiology.24 Respiratory tract dysbiosis provokes
a dysregulated host immune response, which in turn alters the
growth conditions for microorganisms in airways, promoting
further dysbiosis and perpetuating a cycle of inflammation and
disordered microbiota. Differences in the composition of base-
line respiratory tract microbiota might help to explain the so-
called frequent-exacerbator phenotype observed in several dis-
ease states, and might provide novel targets for therapeutic in-
tervention.24
To understand how successful has the immigration of As-
pergillus conidia into the upper and lower respiratory tract the
mycobiome of individual compartments and structures will be
examined.
The fungal mycobiome in sinusitis
The upper airways or upper respiratory tract includes the nose
and nasal passages, paranasal sinuses, the pharynx, and the por-
tion of the larynx above the vocal folds (cords). The lower air-
ways or lower respiratory tract includes the portion of the larynx
below the vocal folds, trachea, bronchi, and bronchioles. It has
been known for a long time that the membranes of the nasal
mucosa are home to a large number of fungi that are found in
individuals both with and without sinus disease. A well-described
mucosal disease in this region is chronic rhinosinusitis. This is re-
garded as a disease of inflammation rather than infection. How-
ever, numerous studies have demonstrated roles for commensal
resident fungi, or their secretory products such as allergens and
secondary metabolites, in the initiation and/or progression of
mucosal inflammation.
Fungal associated infections of the upper respiratory tract are
biofilm diseases. A biofilm is a complex polymicrobial commu-
nity of fungi surrounded by an exopolysaccharide matrix pro-
duced by fungi. Formation of biofilms is a defense mechanism
for fungi that can protect themselves from antifungals and from
the host immune system. Biofilm formation in sinonasal mucosa
has been studied in chronic rhinosinusitis syndrome (CRS) in
multiple studies. It is associated with recurrence of disease, poor
response to treatment, and unfavorable outcome after surgery.
Diverse fungal biofilms have been attributed to the pathogenesis
and phenotypes of CRS.25
The association of fungi with CRS has been investigated in
multiple studies, with controversial results. In the late 1990s,
fungal cultures identified colonization in more than 90% of CRS
patients and drew significant attention to this field. In this way,
several fungal species were identified in CRS.26 Further studies
using nucleic acid amplification techniques showed evidence of
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fungal colonization in the nose in more than 90% of healthy
controls.27
Does Aspergillus cause chronic rhinosinusitis? Recent stud-
ies that used specific primers for PCR analyses of fungi give a
more complete picture of the fungal mycobiome in the nose and
paranasal sinuses. However, the results of these studies have en-
gendered controversies as well. Cleland and colleagues analyzed
nasal swabs of 23 chronic rhinosinusitis (CRS) patients and 11
controls.28 They used 18S ribosomal DNA (rDNA) fungal tag-
encoded FLX amplicon pyrosequencing. This showed that CRS
cases had greater fungal richness than controls. Malassezia was
the most common and abundant species and was found in all
CRS cases at surgery. Aspergillus was found in 365 of the pa-
tients. Aurora and coresearchers analyzed the mycobiome the
sinuses by deep sequencing of 18S rDNA.29 They found qual-
itatively similar mycobiomes in CRS and controls but greater
diversity and abundance of fungi in the CRS group. Cryptococ-
cus neoformans was the most abundant fungus in both CRS and
control cases, although it was more prevalent in the CRS group
(90% vs 61%). Boase and colleagues focused on pathogenic
taxa using 16 primer pairs for PCR, which could survey nearly
all pathogenic fungal species, but could not find evidence of
pathogenic fungal DNA in most of the cases studied.30 Three
CRS patients with nasal polyps cases were positive (two for As-
pergillus fumigatus and one for Bipolaris papendorfii), while all
CRSsNP cases and healthy controls were negative.
A seminal study by Burzina and colleagues examined the
biodiversity of fungi isolated from the nasal mucus of patients
suffering from chronic rhinosinusitis and from healthy persons,
monitored over 28 months by culture and PCR and sequenc-
ing.27 Patients were primarily from the southern province of
Styria in Austria. Mucus samples were obtained by flushing the
noses of patients with saline or by endoscopic sinus surgery.
Altogether, 619 strains of fungi were cultivated from 233 sub-
jects. Eighty-one species were identified, with a maximum of nine
different species per person. The most prevalent species were
Penicillium, Aspergillus, Cladosporium, Alternaria, and Aure-
obasidium. Whereas Aspergillus and Penicillium spp. occurred
in more or less the same numbers throughout the year, Cladospo-
rium spp., Alternaria spp. and Aureobasidium pullulans showed
a significantly higher occurrence during late summer and early
autumn.
Mycobiome of the oral cavity
The concept of a “core healthy oral mycobiome” was intro-
duced in 2010 by Ghannoum and colleagues when they char-
acterized the oral mycobiome of 20 healthy adults.31 Analysis
of ITS1F/ITS2 sequences identified a total of 85 fungal genera
within the oral cavity, 11 of which related to non-culturable fun-
gal genera. Although the exact number of fungal genera in the
oral cavity varied between participants (range 5–39), a core set
of genera were identified in the oral cavities of more than 20% of
study participants: Candida (75%); Cladosporium (60%); Au-
reobasidium (50%); Aspergillus (35%); Fusarium (30%), and
Cryptococcus (20%). The high prevalence of Candida in the
oral cavity is consistent with previous culture-based studies, and
subsequent molecular studies confirmed the high prevalence of
Candida spp. within the oral cavity.
Another study found that when the oral fungal microbiome
was investigated in 30 individuals with and without periodon-
titis, moulds were recovered from all participants and yeast
from 92.5%.32 The most frequently isolated fungi were Can-
dida, Rhodotorula, Penicillium, Aspergillus, and Cladosporium.
The mycobiome of the oral cavity of individuals with and
without human immunodeficiency virus (HIV) has been an-
alyzed.33 Although both Candida and Penicillium were iso-
lated from the oral cavity of all individuals, significant differ-
ences in the overall mycobiome profiles were identified between
healthy and disease states. For example, Alternaria, Epicoccum,
and Trichosporon were found only in HIV positive patients,
while Pichia, Cladosporium, and Fusarium were associated with
health.
The mycobiome of the respiratory tract in the context
of specific diseases
The recent application of mass sequencing techniques with
high-performance platforms and amplification of total DNA in
the respiratory secretions of patients with chronic bronchopul-
monary disease has made it possible to detect a wider range
of microorganisms than was the case with conventional cul-
tures. Differences have been observed between the yeast identi-
fied in healthy individuals and those detected in patients with
bronchiectasis or asthma, suggesting that they could have a dif-
ferent significance in different contexts. Most of the research un-
dertaken on the microbiome in respiratory disease has involved
small sample sizes, as well as sputum samples (rather than bron-
choaspiration), and as a result, its clinical importance is still
unclear. The main focus has been on the bacterial microbiome
in cystic fibrosis (CF), asthma, and COPD, with only a few stud-
ies of bronchiectasis. In the case of CF, fungi are detected more
often during exacerbations.
Apart from the infections that are already known to be caused
by fungi, the lung mycobiome can have inflammatory effects that
can cause or aggravate chronic respiratory disease.34 Like bac-
teria, fungi also contain pathogen-associated molecular patterns
(PAMP), which are recognizable by pattern recognition recep-
tors that activate macrophages, B and T cells, thereby triggering
inflammation. An understanding of the innate and inflammatory
consequences of exposure to Aspergillus species is critical in
accounting for disease manifestations and preventing sequelae.
The major components of the innate immune system involved
in recognition and removal of the fungus include phagocytosis,
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antimicrobial peptide production, and recognition by pattern
recognition receptors. The cytokine response is also critical fa-
cilitating cell-to-cell communication and promoting the initia-
tion, maintenance, and resolution of the host response.35 Given
that fungi are omnipresent in the environment, the respiratory
system’s continuous exposure to them and their capacity to trig-
ger an inflammatory process suggests that the mycobiome may
contribute to lung damage. Most studies have found that a re-
duction in fungal diversity in respiratory diseases correlates with
a poorer lung function. This reduced diversity could be caused by
the excessive growth of one fungal species or by the elimination
of other species.
Cystic fibrosis
The mycobiome of the respiratory tract of CF patients is com-
plex. Botterel and colleagues compared the fungal diversity
of sputa from adult CF patients during non-exacerbation pe-
riod by culture-based and molecular methods, and ultra-deep-
sequencing (UDS).36 Sputum samples from four CF patients were
cultured and analyzed by DNA extractions followed by termi-
nal restriction fragment length polymorphism analysis through
resolution of bacterial ribosomal gene (rDNA) fragments, and
cloning plus sequencing of part of fungal rRNA genes. These
approaches were compared with the UDS method targeting 16S
rDNA gene and the internal transcribed spacer (ITS) 2 region of
rDNA. A total of 18 fungal genera were detected from the four
patients. The mean number of genera detected by UDS per pa-
tient was statistically higher than by culture or whole genome se-
quencing (WGS) methods. Patients with severe airway disease as
assessed by standard spirometry exhibited a reduced fungal and
bacterial diversity. UDS approach evaluates more extensively the
diversity of fungal and bacterial flora compared with cultures.
The authors concluded that their study, despite the small num-
ber of enrolled patients, highlighted benefits of UDS for fungal
detection. Using the UDS method, they were able to detect taxa
not revealed by culture or WGS, at relatively high proportions,
and to designate a mycobiota core composed of Aspergillus be-
longing to the Fumigati section and Penicillium spp., which was
consistent with a previous history of A. fumigatus colonization.
Similar to other analyses the study showed a reduced diversity of
fungal and communities in patients with impaired lung function
(low FEV1 and FCV).36
Chronic obstructive pulmonary disease
Exacerbations of COPD are associated with high mortality,
rapid decrease in lung function, and increased health-care costs.
Frequency of exacerbations increases with severity of airway
obstruction, but many patients experience exacerbations more
frequently than would be predicted by disease severity alone (the
so-called frequent exacerbator phenotype).24 Exacerbations are
also associated with systemic inflammation, airway inflamma-
tion, and increased airway obstruction due to edema, increased
sputum production, and bronchoconstriction.24 The primary
fungus enriched in the lungs of individuals with COPD in the
setting of HIV is Pneumocystis.33 Pneumocystis colonization has
been postulated to contribute to COPD by stimulating inflamma-
tion and release of matrix metalloproteases, which can damage
the lung.33
COPD is present in 2% of patients dying from invasive
pulmonary fungal disease. A second presentation in COPD
patients is chronic pulmonary aspergillosis. A third presenta-
tion is aspergilloma. It is usually asymptomatic although fatal
hemoptysis and/or invasion of pulmonary tissue can develop.
Finally, patients who are admitted to the ICU with an exac-
erbation of their disease, can develop invasive aspergillosis with
almost 100% mortality rate (reviewed in Ostrosky-Zeichner and
Al-Obaaidi37).
Asthma
Exacerbations cause much of the mortality, morbidity, and
health-care expenses of asthma. Precipitants include allergens,
air pollution, and exercise, although, as is the case in COPD,
some patients exhibit a frequent exacerbator phenotype indepen-
dent of other risk factors. In addition to viral infections asthma
exacerbations are strongly associated with fungal exposure and
fungal sensitization.
Little is known about the mycobiome in fungal lung disease.
Fraczek and colleagues determined the mycobiome in lungs of
individuals with well-characterized fungal disease and looked at
the association with corticosteroid therapy.38 Following bron-
choscopy, ribosomal internal transcribed spacer region 1 DNA
was amplified and sequenced and fungal load determined by
real-time PCR. Patients with bronchopulmonary aspergillosis,
severe asthma with fungal sensitization, severe asthma not sen-
sitized to fungi, mild asthma patients, and 10 healthy control
subjects were included in the study. The mycobiome was highly
varied with severe asthmatics carrying higher loads of fungus.
Healthy individuals had low fungal loads, mostly poorly charac-
terized Malasezziales. Individuals receiving steroid therapy had
significantly higher levels of Aspergillus and total fungus in their
bronchoalveolar lavage.
Bronchiectasis
Little is known about the epidemiology and fungal biodiver-
sity of bronchiectasis.34 In bronchiectasis patients, deteriorated
mucociliary clearance, generally due to prior colonization by
bacterial pathogens, and thick mucus accumulation, the persis-
tence of fungal spores in the respiratory tract. The most preva-
lent fungi in these patients are Candida albicans and Aspergillus
fumigatus (Table 1); these are almost always isolated with bacte-
rial pathogens like Haemophillus influenzae and Pseudomonas
aeruginosa, making it very difficult to define their clinical sig-
nificance. Analysis of the mycobiome enables us to detect a
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Table 1. Species most frequently found in patients with bronchiec-
tasis not associated with cystic fibrosis.
Yeasts Filamentous fungi
Candida albicans Aspergillus fumigatus
Candida glabrata Aspergillus niger
Candida parapsilosis Aspergillus terreus
Saccharomyces cerevisiae Scedosporium apiospermum
Trichosporon beigellii Penicillium species
Exophiala dermatitidis Fusarium species
(Adapted from Máiz et al.34).
greater diversity of microorganisms than with conventional cul-
tures. The results have shown a reduced fungal diversity in most
chronic respiratory diseases, and that this finding correlates with
poorer lung function.
Aspergillus spp. are the most prevalent filamentous fungi
found in bronchiectasis patients.34 A. fumigatus is the most com-
mon species, followed by A. niger, A. terreus, and A. flavus.
However, there are huge variations in the prevalence of the
fungi isolated in studies. The prevalence of Aspergillus spp. in
bronchiectasis ranges from 7% to 24%. The distribution of the
species in bronchiectasis patients varies according to the geo-
graphical area, with a high prevalence of A. niger and A. terreus
in Japan and of A. flavus in India and China.
The clinical significance of fungi in cultures of respiratory
samples taken from bronchiectasis patients has still not been
clearly defined. Further studies that would make it possible to
standardize and evaluate both the microbiological criteria for
defining chronic colonization and the methods used for cultur-
ing and identifying fungi would provide us with more precise
knowledge of the genera and species involved, and of the role
that fungi play in the clinical evolution of bronchiectasis patients.
Very recently, understanding the composition and clinical im-
portance of the fungal mycobiome in patients has been identi-
fied as a key topic in a “research priorities” consensus state-
ment for bronchiectasis.39 As part of the CAMEB study (a mul-
ticenter cross-sectional Cohort of Asian and Matched European
Bronchiectasis patients) the respiratory mycobiome was deter-
mined in 238 patients by sequencing the 18S-28S rRNA inter-
nally transcribed spacer regions ITS1 and ITS2. Specific qPCR
for detection of and conidial quantification for a range of airway
Aspergillus species was performed. The mycobiome of patients
with bronchiectasis was characterized by specific fungal genera
including Aspergillus, Cryptococcus, and Clavispora. A. fumi-
gatus (in Singapore/Kuala Lumpur, Malaysia) and A. terreus (in
Dundee, UK) dominated the mycobiome profiles. Interestingly,
A. terreus was associated with exacerbations. High frequencies
of Aspergillus-associated disease including sensitization and al-
lergic bronchopulmonary aspergillosis were detected. Each re-
vealed distinct mycobiome profiles and associated with more
severe disease, poorer pulmonary function and increased exac-
erbations. This study concluded that the pulmonary mycobiome
is of clinical relevance in bronchiectasis and the authors advo-
cate that screening for Aspergillus-associated disease should be
considered even in apparently stable patients.
Lung transplant recipients
Long-term survival after lung transplantation is limited by in-
fectious complications and by bronchiolitis obliterans syndrome
(BOS), a form of chronic rejection linked in part to microbial trig-
gers including fungi. Charlson and colleagues defined microbial
populations in the respiratory tract of transplant patients com-
prehensively using unbiased high-density sequencing.40 Lungs
were sampled by bronchoscopy and the upper respiratory tract
by oropharyngeal wash. Fungal internal transcribed spacer se-
quencing was used to profile organisms present. Fungal popula-
tions were typically dominated by Candida in both sites or by
Aspergillus in bronchoalveolar lavage fluid but not in oropharyn-
geal wash. This study demonstrated that the fungal communities
in lung transplant recipients differ in structure and composition
from healthy subjects. This understanding is of paramount im-
portance when assessing the significance of Aspergillus in the
cystic fibrosis setting.
What do we breathe in?
Colonization by environmental fungi, including Aspergillus may
become significant, and eventually result in Aspergillus-related
lung disease when the microbiological composition of the nor-
mal flora in the respiratory tract is disturbed, such as in the
case of an underlying disease, an altered immunological status
of the host, or a decrease in ciliary activity of the mucous pul-
monary epithelium. The underlying diseases that predispose to
aspergillosis could thus provide significant insights into which
alterations in the microbiome might predispose to aspergillosis.
The fungi that reside in the human lungs represent an under-
studied but medically relevant community. From the few studies
published on the lung mycobiome, it is clear that there are fungi
in both the healthy and diseased respiratory tract, that these
fungi vary widely between individuals, and that there is a trend
toward lower fungal diversity among individuals with chronic or
progressive respiratory disease. Another dimension to the above
discussion is the persistence or clearance of fungal conidia and
hyphal fragments in healthy or debilitated individuals from the
various levels of the respiratory tract.41 The primary route of
human infection is via the inhalation of these airborne conidia,
followed by conidial deposition in the bronchioles or alveolar
spaces. In healthy individuals, conidia that are not removed
by mucociliary clearance encounter epithelial cells or alveolar
macrophages, the primary resident phagocytes of the lung. Alve-
olar macrophages are primarily responsible for the phagocytosis
and killing of Aspergillus conidia as well as the initiation of a
proinflammatory response that recruits neutrophils (one type of
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polymorphonuclear cell [PMN]) to the site of infection. Conidia
that evade macrophage killing and germinate become the target
of infiltrating neutrophils that are able to destroy hyphae. The
risk of developing IA results primarily from a dysfunction in
these host defenses in combination with fungal attributes that
permit A. fumigatus survival and growth in this pulmonary en-
vironment.
It is patently clear from the surveys reviewed that healthy
individuals and patients are exposed to a diverse collection of
fungal taxa and species in outdoor and indoor environments.
In many geographical areas A. fumigatus is able to grow and
sporulate on a variety of organic substrates in outdoor niches and
release conidia into the air. Mycobiome studies of air and dust
demonstrate this very clearly. The appearance of Aspergillus in
indoor locations is most likely as a result of migration of conidia
from outside considering that there are few substrates and micro-
environments to support the growth of Aspergillus in homes.
The interesting question is whether the lung mycobiome reflects
the diversity of fungi in outdoor and indoor environments. It is
suggested, based on the limited analysis of the lung mycobiome,
reviewed here, that the answer is no. Aspergillus species are
underrepresented in many respiratory tract mycobiome analyses,
but this appears to be highly dependent on the analysis platform
used.
Molecular analysis of mucosal surfaces and respiratory secre-
tions from the respiratory tract has shown that fungal respiratory
communities are far more complex than culture alone would sug-
gest. For example, analysis of sputum samples from individuals
with and without cystic fibrosis demonstrated that over 60%
of organisms identified by sequencing were not recovered by
culture, although it should be noted that culture techniques for
respiratory samples are from optimal. Current national and in-
ternational standards are woefully inadequate. Individuals with
decreased lung function (as measured by FEV1 and FVC) har-
bour less diverse fungal and bacterial communities, which tend
to be dominated by only a small number of organisms. Inter-
estingly, bacterial communities with high abundances of Pseu-
domonas are more likely to be associated with high abundances
of Candida species than with Aspergillus fumigatus. A similar
phenomenon has been seen in lung transplant patients, in which
Aspergillus species were never isolated in individuals with bac-
terial communities dominated by Pseudomonas.
There is a pronounced decreased diversity of fungal commu-
nities with the progression of chronic lung disease and exac-
erbations. It is proposed that exacerbations provoked by fungal
exposure are occasions of respiratory tract dysbiosis—a disorder
of the respiratory tract fungal ecosystem with negative effects on
host biology. Respiratory tract dysbiosis provokes a dysregulated
host immune response, which in turn alters growth conditions
for fungi in airways, promoting further dysbiosis and perpetuat-
ing a cycle of inflammation and disordered mycobiota: a perfect
environment for aspergillosis.
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